TIMP3 — TIMP metallopeptidase inhibitor 3

The TIMP3 gene provides instructions for making a protein called Tissue Inhibitor of Metalloproteinases 3. This protein acts like a molecular brake, controlling the activity of other enzymes that break down the structural support network of cells, known as the extracellular matrix. In the eye, TIMP3 is crucial for maintaining a healthy layer called Bruch's membrane, which sits beneath the retina and helps regulate the flow of nutrients and waste. It also helps prevent the abnormal growth of blood vessels in the eye. When the TIMP3 gene is mutated, it produces an abnormal protein that doesn't work correctly. Instead of doing its job, the faulty protein builds up in Bruch's membrane, causing it to thicken and become dysfunctional. This buildup leads to a condition called Sorsby fundus dystrophy (SFD). In SFD, the abnormal membrane triggers the growth of fragile, leaky blood vessels under the retina, a process called choroidal neovascularization. These leaky vessels can cause scarring and severe damage to the macula, the part of the eye responsible for sharp, central vision. For patients and families, a diagnosis of SFD means a high risk of losing central vision, usually starting in adulthood (between the ages of 30 and 50). The disease is inherited in an autosomal dominant pattern, meaning that if one parent has the mutated gene, each child has a 50% chance of inheriting it and developing the condition. While there is currently no cure for SFD, treatments like anti-VEGF injections can help manage the abnormal blood vessel growth and slow down vision loss. Genetic counseling is important for affected families to understand the risks and inheritance of the disease.

Gene description: Encodes an inhibitor of metalloproteinases, crucial for extracellular matrix remodeling in the retina.

Patient and family guide: The TIMP3 gene provides instructions for making a protein called Tissue Inhibitor of Metalloproteinases 3. This protein acts like a molecular brake, controlling the activity of other enzymes that break down the structural support network of cells, known as the extracellular matrix. In the eye, TIMP3 is crucial for maintaining a healthy layer called Bruch's membrane, which sits beneath the retina and helps regulate the flow of nutrients and waste. It also helps prevent the abnormal growth of blood vessels in the eye. When the TIMP3 gene is mutated, it produces an abnormal protein that doesn't work correctly. Instead of doing its job, the faulty protein builds up in Bruch's membrane, causing it to thicken and become dysfunctional. This buildup leads to a condition called Sorsby fundus dystrophy (SFD). In SFD, the abnormal membrane triggers the growth of fragile, leaky blood vessels under the retina, a process called choroidal neovascularization. These leaky vessels can cause scarring and severe damage to the macula, the part of the eye responsible for sharp, central vision. For patients and families, a diagnosis of SFD means a high risk of losing central vision, usually starting in adulthood (between the ages of 30 and 50). The disease is inherited in an autosomal dominant pattern, meaning that if one parent has the mutated gene, each child has a 50% chance of inheriting it and developing the condition. While there is currently no cure for SFD, treatments like anti-VEGF injections can help manage the abnormal blood vessel growth and slow down vision loss. Genetic counseling is important for affected families to understand the risks and inheritance of the disease.

Gene function: TIMP3 plays a vital role in regulating the extracellular matrix in the retina, particularly in Bruch's membrane. Its dysfunction leads to abnormal accumulation of material, contributing to macular degeneration and affecting retinal pigment epithelium health and photoreceptor support.

Protein structure: The TIMP3 protein is a secreted glycoprotein consisting of 211 amino acids. It is structurally divided into two main domains: an N-terminal domain and a C-terminal domain. The N-terminal domain, which comprises about two-thirds of the mature protein (approximately 120 amino acids), is primarily responsible for the inhibitory activity against matrix metalloproteinases (MMPs). It binds to the active site of MMPs, blocking their catalytic function. The C-terminal domain makes up the remaining one-third of the protein and is crucial for the unique properties of TIMP3, particularly its ability to bind tightly to the extracellular matrix (ECM). This domain interacts with sulfated glycosaminoglycans in the ECM, anchoring TIMP3 to the tissue matrix. The protein structure is stabilized by several intramolecular disulfide bonds. Most pathogenic mutations associated with Sorsby fundus dystrophy occur in the C-terminal domain and introduce an unpaired cysteine residue, which is thought to cause abnormal intermolecular disulfide bonding and the subsequent accumulation of the protein in the ECM.

Molecular function: The TIMP3 gene encodes the Tissue Inhibitor of Metalloproteinases 3, a secreted protein that plays a crucial role in regulating the extracellular matrix (ECM). TIMP3 functions as a potent inhibitor of matrix metalloproteinases (MMPs), a disintegrin and metalloproteinases (ADAMs), and ADAMs with thrombospondin motifs (ADAMTSs). By irreversibly binding to the catalytic zinc cofactor of these enzymes, TIMP3 prevents the degradation of ECM components, thereby maintaining tissue structure and homeostasis. In the retina, TIMP3 is a key component of Bruch's membrane, a specialized ECM layer that separates the retinal pigment epithelium (RPE) from the choroidal vasculature. TIMP3 regulates the turnover of Bruch's membrane and inhibits angiogenesis by blocking the binding of vascular endothelial growth factor (VEGF) to its receptor, VEGFR-2. This anti-angiogenic function is vital for preventing the abnormal growth of blood vessels (choroidal neovascularization) into the retina. Additionally, TIMP3 is involved in modulating inflammation and apoptosis, further highlighting its multifaceted role in cellular biology and tissue maintenance.

Expression pattern: The TIMP3 gene is widely expressed in various tissues throughout the body, with significant expression in the eye, particularly in the retinal pigment epithelium (RPE) and Bruch's membrane. In the eye, TIMP3 is a major component of Bruch's membrane, where it plays a critical role in regulating extracellular matrix (ECM) turnover and maintaining the structural integrity of the retina. Beyond the eye, TIMP3 is expressed in the heart, lungs, kidneys, and brain. It is involved in various physiological processes, including cardiac remodeling, where its levels are reduced in ischemic and dilated cardiomyopathy. The broad expression pattern of TIMP3 underscores its essential role in ECM homeostasis and its involvement in multiple systemic and tissue-specific functions.

Mutation spectrum: The mutation spectrum of the TIMP3 gene is primarily characterized by missense mutations, with the vast majority introducing a novel cysteine residue in the C-terminal domain of the protein. These mutations disrupt the normal folding and function of TIMP3, leading to its abnormal accumulation in Bruch's membrane. To date, over 15 different pathogenic variants in TIMP3 have been identified as causing Sorsby fundus dystrophy (SFD). Hotspot regions for these mutations are predominantly located in the C-terminal domain, particularly involving exon 5 of the gene. Founder mutations have also been reported, such as the Ser156Cys mutation, which has been identified in multiple families of British descent, suggesting a common ancestral origin. The introduction of an unpaired cysteine residue is a consistent feature among these pathogenic variants, underscoring the critical role of proper disulfide bond formation in the normal function of TIMP3.

Pathogenic variants: 1. p.Ser156Cys (S156C) - One of the most common and well-characterized mutations, often associated with a founder effect in British populations. It causes classic Sorsby fundus dystrophy with early-onset choroidal neovascularization. 2. p.Tyr152Cys (Y152C) - A novel mutation identified in families with SFD, leading to the typical accumulation of TIMP3 and subsequent macular dystrophy. 3. p.Ser179Cys (S179C) - This mutation has been extensively studied in animal models and is known to promote angiogenesis and CNV via an FGFR-1-dependent pathway. 4. p.Tyr191Cys (Y191C) - A variant that impairs the binding of TIMP3 to MMP2/9, contributing to the pathogenesis of SFD by disrupting normal ECM regulation. 5. p.Glu139Lys (E139K) - A missense mutation that, unlike the typical cysteine-introducing mutations, also causes SFD, highlighting the importance of this specific residue in TIMP3 function.

Clinical significance: Mutations in the TIMP3 gene are the primary cause of Sorsby fundus dystrophy (SFD), a rare, autosomal dominant macular dystrophy. Clinically, SFD is characterized by bilateral loss of central vision, typically beginning in the third to fifth decades of life. The disease shares many phenotypic similarities with age-related macular degeneration (AMD) but has an earlier onset. Patients often present with night blindness or sudden loss of visual acuity due to the development of choroidal neovascularization (CNV). The severity of the disease can vary, but it generally progresses to significant visual impairment. The hallmark of SFD is the accumulation of thick lipid-containing deposits under the retinal pigment epithelium (RPE), similar to drusen seen in AMD. These deposits disrupt the normal function of the RPE and lead to the formation of CNV, which can cause subretinal hemorrhage, exudation, and eventually disciform scarring. While SFD is primarily an ocular disease, some studies have suggested potential systemic features, although these are less well-defined. The progressive nature of the disease and the high risk of CNV make early diagnosis and monitoring crucial for managing the condition and preserving vision as long as possible.

Inheritance: Autosomal Dominant

Chromosomal location: 22q12.3

Genotype-phenotype correlations: Genotype-phenotype correlations in Sorsby fundus dystrophy (SFD) are complex, but some patterns have emerged. Most pathogenic variants in TIMP3 are missense mutations that introduce a novel cysteine residue in the C-terminal domain of the protein. These mutations are thought to cause abnormal intermolecular disulfide bonding, leading to the accumulation of mutant TIMP3 in Bruch's membrane. While the clinical presentation of SFD is generally consistent, there can be variability in the age of onset and the severity of the disease among different families and even within the same family. Some specific mutations, such as the Ser156Cys mutation, have been extensively studied and are associated with the classic features of SFD, including early-onset CNV. Other mutations may present with slightly different clinical courses, such as a later onset of symptoms or a more slowly progressive disease. However, the overarching phenotype remains the development of macular dystrophy and CNV, driven by the accumulation of dysfunctional TIMP3.

Research and therapeutic approaches: Currently, there are no approved gene therapies or definitive cures for Sorsby fundus dystrophy (SFD). The standard of care focuses on managing the complications of the disease, primarily the development of choroidal neovascularization (CNV). The most effective current treatment involves the off-label use of intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents, such as bevacizumab or ranibizumab. These injections help to reduce the abnormal blood vessel growth and leakage, thereby preserving central vision for a period. However, this approach requires repeated injections and does not address the underlying genetic defect or the accumulation of mutant TIMP3. In terms of pipeline therapies, several investigational approaches are being explored. Gene therapy is a major area of interest, with research focusing on delivering a healthy copy of the TIMP3 gene or using CRISPR/Cas9 base editing to correct the specific point mutations responsible for SFD. Preclinical studies using adeno-associated virus (AAV) vectors to deliver gene editing tools have shown promise in animal models, but these have not yet advanced to clinical trials for SFD. Other potential strategies include the use of small molecules or antisense oligonucleotides to reduce the expression of the mutant TIMP3 protein or to enhance the clearance of the abnormal deposits in Bruch's membrane. While these approaches are still in the early stages of development, they offer hope for more targeted and durable treatments in the future.

Diagnostic testing: Diagnosis of Sorsby fundus dystrophy (SFD) involves a combination of clinical evaluation, imaging studies, and genetic testing. Clinical evaluation typically includes a comprehensive eye exam, funduscopy, and optical coherence tomography (OCT) to detect the characteristic sub-RPE deposits and choroidal neovascularization (CNV). Fluorescein angiography may also be used to identify and monitor CNV. The definitive diagnosis of SFD is confirmed through genetic testing, which identifies heterozygous pathogenic variants in the TIMP3 gene. This can be achieved through targeted gene panels for inherited retinal diseases or whole exome sequencing. Genetic counseling is highly recommended for patients and their families, as SFD follows an autosomal dominant inheritance pattern. This means that each child of an affected individual has a 50% chance of inheriting the mutated gene. Genetic counseling helps families understand the risks, the natural history of the disease, and the available options for family planning and early intervention.

Animal models: Key animal models used to study TIMP3 include the TIMP3 knockout mouse and the TIMP3 Ser156Cys knock-in mouse. The TIMP3 knockout mouse model (Timp3-/-) demonstrates spontaneous air space enlargement in the lungs and abnormal tumor necrosis factor (TNF) activity leading to hepatic inflammation. In the context of the eye, TIMP3 knockout mice exhibit increased choroidal neovascularization (CNV) following laser injury, suggesting a loss of function mechanism. They also show abnormal vessel formation in the choroid. To better mimic Sorsby fundus dystrophy (SFD), researchers generated a knock-in mouse model carrying the disease-related Ser156Cys mutation (equivalent to the human Ser156Cys mutation). The TIMP3-S179C+/+ knock-in mice exhibit increased CNV with a striking increase in the auto-phosphorylation of FGFR-1 and increased MMP2 activity. These models have revealed that mutant TIMP3 can promote angiogenesis and CNV via an FGFR-1-dependent pathway, providing crucial insights into the pathophysiology of SFD and potential therapeutic targets.

Population genetics: Sorsby fundus dystrophy (SFD) is a very rare condition, and the overall carrier frequency of TIMP3 pathogenic variants in the general population is extremely low. However, certain mutations exhibit founder effects in specific populations. For example, the p.Ser156Cys mutation has been identified in multiple families of British descent, indicating a common ancestor. While large-scale population genetics data for SFD are limited due to its rarity, studies on the broader implications of TIMP3 variants suggest that certain polymorphisms (e.g., rs9621532) may influence the risk of developing other conditions, such as neovascular age-related macular degeneration (nAMD), by altering TIMP3 transcription levels.

Selected references: 1. Apte SS, et al. Cloning of the cDNA encoding human tissue inhibitor of metalloproteinases-3 (TIMP-3) and mapping of the TIMP3 gene to chromosome 22. Genomics, 1994. PMID: 8188283 2. Weber BH, et al. Mutations in the tissue inhibitor of metalloproteinases-3 (TIMP3) in patients with Sorsby's fundus dystrophy. Nat Genet, 1994. PMID: 7894489 3. Qi JH, et al. A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat Med, 2003. PMID: 12612543 4. Langton KP, et al. Sorsby's fundus dystrophy mutations impair turnover of TIMP-3 by retinal pigment epithelial cells. Hum Mol Genet, 2005. PMID: 16204289 5. Gliem M, et al. Sorsby Fundus Dystrophy: Novel Mutations, Novel Phenotypic Characteristics, and Treatment Outcomes. Invest Ophthalmol Vis Sci, 2015. PMID: 26024105 6. Fan D, Kassiri Z. Biology of Tissue Inhibitor of Metalloproteinase 3 (TIMP3), and Its Therapeutic Implications in Cardiovascular Pathology. Front Physiol, 2020. PMID: 32612540 7. Vergaro A, et al. Disease-Causing TIMP3 Variants and Deep Phenotyping of Two Czech Families with Sorsby Fundus Dystrophy Associated with Novel p.(Tyr152Cys) Mutation. Int J Mol Sci, 2024. PMID: 38612554